Last reviewed 2026-05-14 · How we verify

Marketed MMRV_Lot 1 and Lot 2 vaccine

GlaxoSmithKline · Phase 2 active Biologic

Marketed MMRV_Lot 1 and Lot 2 vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development. Also known as: ProQuad.

At a glance

Generic name	Marketed MMRV_Lot 1 and Lot 2 vaccine
Also known as	ProQuad
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Marketed MMRV_Lot 1 and Lot 2 vaccine CI brief — competitive landscape report
Marketed MMRV_Lot 1 and Lot 2 vaccine updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about Marketed MMRV_Lot 1 and Lot 2 vaccine

What is Marketed MMRV_Lot 1 and Lot 2 vaccine?

Marketed MMRV_Lot 1 and Lot 2 vaccine is a Biologic drug developed by GlaxoSmithKline.

Who makes Marketed MMRV_Lot 1 and Lot 2 vaccine?

Marketed MMRV_Lot 1 and Lot 2 vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Marketed MMRV_Lot 1 and Lot 2 vaccine also known as anything else?

Marketed MMRV_Lot 1 and Lot 2 vaccine is also known as ProQuad.

What development phase is Marketed MMRV_Lot 1 and Lot 2 vaccine in?

Marketed MMRV_Lot 1 and Lot 2 vaccine is in Phase 2.

Manufacturer: GlaxoSmithKline — full pipeline
Also known as: ProQuad